Novel management of ovarian vein thrombosis: A case report

Naoum, Joseph J.; Mohsen, Amani; Daher, Jihad; Eid, Toufic

doi:10.1016/j.jsps.2018.03.003

Cited by 11 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight patients with OVT treated with DOACs were included in the study by Janczak et al assessing the treatment of VTE in atypical locations, 10 while 5% of 219 women with OVT included in the study by Lenz et al 74 received direct factor Xa inhibitors; however, separate outcome data were not provided. There are 3 published case reports evaluating the use of rivaroxaban 86,87 or apixaban 88 in young women with OVT, with promising results. Finally, Covut et al 89 retrospectively assessed the treatment of 36 women with OVT evaluated at the Cleveland Clinic (United States) in the years 2012‐2018.…”

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer drug interactions, faster onset of action, shorter half‐life, and lower risk of major and intracranial bleeding. Although the evidence on the use of DOACs in patients with unusual‐site venous thromboembolism (VTE) is limited to a few, small randomized controlled trials, these drugs are increasingly used in clinical practice, and several observational cohort studies have been published recently. This narrative review will describe the latest evidence for the use of the DOACs in patients with thrombosis in atypical locations (splanchnic, cerebral, upper extremity, ovarian, and renal vein thrombosis) and will provide some practical advice for their use in patients with unusual‐site VTE.

show abstract

Section: Ovarian Vein Thrombosismentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Duration of treatment ranges from three to six months among authors and lifelong treatment for hypercoagulable diseases [ 7 ]. While some studies advocate the use of Vitamin K antagonists [ 5 ], others prefer low molecular weight heparin [ 11 ], although one study has demonstrated clot resolution with rivaroxaban [ 12 ]. One study showed that the treatment guidelines for lower extremity thrombosis could be extrapolated to OVT [ 13 ], and hence, our patient was prescribed apixaban for treatment.…”

Section: Discussionmentioning

confidence: 99%

Ovarian Vein Thrombosis Can Be a Complication of Hysteroscopy

Kumar

Gupta

2021

Cureus

View full text Add to dashboard Cite

Ovarian vein thrombosis is not well understood, and there is no consensus regarding treatment. It can present with subtle symptoms and is not usually high on the list of differentials. Traditionally, most cases are linked to pregnancy and postpartum state, but our case adds to the growing list of non-puerperal patients diagnosed with ovarian vein thrombosis after an outpatient procedure. In an era where there is a drive for minimally invasive procedures and shorter hospital stays, there is a need to have specific guidelines to direct the diagnosis and treatment of this rare form of thromboembolism.

show abstract

“…For this reason, the British Committee for Standards in Haematology recommends the application of anti-coagulant therapy 3-6 months after diagnosed POVT. For successful treatment of the POVT, the use of LMWH and rivaroxaban over a period of six months is recommended, followed by antiagreggation sulodexide therapy to prevent the risk of relapse [13]. In patients with postpartum POVT, the use of prophylactic doses of anticoagulant drugs is advised during the next pregnancy and six weeks postpartum [14].…”

Section: Discussionmentioning

confidence: 99%

Management of the postpartum ovarian and partial cava inferior vein thrombosis

2020

Clinical and Experimental Obstetrics & Gynecology

View full text Add to dashboard Cite

Postpartum ovarian vein thrombosis (POVT) is a rare but very dangerous complication with possible lethal outcome. Here the authors present a case of POVT with propagation in cava inferior vein, which was diagnosed fourth day after delivery by cesarean section. Case Report: A 27-year-old female with fever complained of pain in the area of the right side of the abdomen, in the ileocecal region three days after premature delivery by caesarean section. Right ovarian venous thrombosis and partial cava inferior vein thrombosis was demonstrated on sonography and confirmed with computed tomography. She was treated with antibiotics and anticoagulation therapy with good response. Conclusion: If women after delivery have an elevated temperature with abdominal pain and leukocytosis in laboratory analyzes, it is always necessary to think of the POVT. Early recognition and therapy are crucial.

show abstract

Novel management of ovarian vein thrombosis: A case report

Cited by 11 publications

References 11 publications

Direct oral anticoagulants for unusual‐site venous thromboembolism

Direct oral anticoagulants for unusual‐site venous thromboembolism

Ovarian Vein Thrombosis Can Be a Complication of Hysteroscopy

Management of the postpartum ovarian and partial cava inferior vein thrombosis

Contact Info

Product

Resources

About